---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-075034"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:27:44.133392+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma Q3 fiscal 2025 net loss narrows to $9.2M; LYMPHIR launch on track for Q4

## Summary
- Net loss of $9.2M ($0.80 per share) vs $10.6M ($1.57 per share) in the prior-year quarter.
- Cash and equivalents $6.1M at June 30; raised $12.5M in gross financings during the quarter.
- LYMPHIR launch for cutaneous T-cell lymphoma planned Q4 2025; manufacturing and distribution agreements in place.
- Citius Oncology raised additional $9M in July 2025 to fund pre-launch activities.
- Mino-Lok discussions with FDA continue; evaluating best path forward for antibiotic lock solution.

## SEC filing metadata
- accession: 0001213900-25-075034
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/0001213900-25-075034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/ea0252899-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-075034
- JSON: https://secwatch.observer/filing/0001213900-25-075034.json
- Plain text: https://secwatch.observer/filing/0001213900-25-075034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.